Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: Relevance of kidney volume and dose rate in finding a dose-effect relationship

Journal of Nuclear Medicine

Volumn 46, Issue 1 SUPPL., 2005, Pages

  Barone, Raffaella ^a   Borson Chazot, Françoise ^a   Valkema, Roelf ^b   Walrand, Stéphan ^a   Chauvin, Franck ^c   Gogou, Lida ^a   Kvols, Larry K ^d   Krenning, Eric P ^b   Jamar, François ^a   Pauwels, Stanislas ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c CENTRE LÉON BÉRARD   (France)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

90Y DOTA Tyr3 octreotide; Kidney dosimetry; Radiation nephropathy; Radionuclide therapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO PHENYL 1 TYROSYL 3 OCTREOTIDE Y 90; UNCLASSIFIED DRUG; YTTRIUM 90; (DOTA(0) PHE(1) TYR(3))OCTREOTIDE; (DOTA(0)-PHE(1)-TYR(3))OCTREOTIDE; DRUG DERIVATIVE; OCTREOTIDE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CREATININE CLEARANCE; DOSIMETRY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; FEMALE; HUMAN; KIDNEY CORTEX; KIDNEY FUNCTION; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; ALGORITHM; ANTIBODY SPECIFICITY; BODY BURDEN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GASTROINTESTINAL TUMOR; KIDNEY; KIDNEY DISEASE; KIDNEY FUNCTION TEST; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PANCREAS TUMOR; RADIATION EXPOSURE; RADIATION INJURY; RADIATION RESPONSE; RADIOMETRY; RELATIVE BIOLOGIC EFFECTIVENESS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICS; TREATMENT OUTCOME;

ADULT; AGED; ALGORITHMS; BODY BURDEN; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGAN SPECIFICITY; PANCREATIC NEOPLASMS; RADIATION INJURIES; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RELATIVE BIOLOGICAL EFFECTIVENESS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS; TREATMENT OUTCOME;

EID: 14844354088     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389-427.
2. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin analogue for cancer treatment. Lancet. 1998; 351:417- 418.
3. de Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: pre-clinical and clinical findings. Semin Nucl Med. 2002;32:133-140.
4. 3- octreotide: the experience of the European Institute of Oncology Group. Semin Nucl Med. 2002;32:141-147.
5. 90Y-DOTATOC. J Nucl Med. 2002;43:610-616.
6. 90Y-SMT 487 in patients with neuroendocrine tumors. J Nucl Med. 2003;44:1556-1560.
7. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. An overview of the results of peptide receptor radionuclide therapy with 3 different radiolabeled somatostatin analogues. J Nucl Med. 2005;46(suppl):62S-66S.
8. 90Y-labeled somatostatin analogues. J Nucl Med. 2005;46(suppl):92S-98S.
9. 90Y-SMT487 (Octreother™) therapy [abstract]. J Nucl Med. 2000;41(suppl):111P.
10. 3-octreotide (SMT487): a phase 1 clinical study - pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging. 2003;30:510-518.
11. 111In- DTPA-octreotide. Eur J Nucl Med. 2001;28:1743-1750.
12. 90Y-DOTATOC. Eur J Nucl Med. 1999;26:877-886.
13. Otte A, Hermann R, Heppeler A, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26:1439-1447.
14. Moll S, Nickeleit V, Mueller-Brand J, Brunner FP, Maecke HR, Mihatsch MJ. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis. 2001;37:847-851.
15. 90Y-DOTATOC. Eur J Nucl Med. 2001;28:1552-1554.
16. Boerman OC, Oyen WJG, Corstens FHM. Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney. Eur J Nucl Med. 2001;28:1447-1449.
17. Stoffel MP, Pollok M, Fries J, Baldamus CA. Radiation nephropathy after radiotherapy in metastatic medullary thyroid carcinoma. Nephrol Dial Transplant. 2001;16:1082-1083.
18. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109-122.
19. 3]octreotide accurate enough to predict thresholds for individual patients? Cancer Biother Radiopharm. 2003;18:619-625.
20. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538-546.
21. 90Y-SMT487 (OctreoTher®) in patients with somatostatin receptor (SS-R) positive tumors [abstract]. J Nucl Med. 2002;43(suppl):P120.
22. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
23. 3]octreotate. J Nucl Med. 2005;46(suppl):83S-91S.
24. Bouchet LG, Bolch WE, Blanco HP, et al. MIRD pamphlet no. 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med. 2003;44:1113-1147.
25. 86Y for nuclear medical applications. Int J Appl Radiat Isot. 1993;44:677-681.
26. Wienhard K, Dahlböm M, Eriksson L, et al. The ECAT EXACT HR: performance of a new high resolution positron scanner. J Comput Assist Tomogr. 1994;18:110-118.
27. Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging. 1994;13:601-609.
28. 86Y. Eur J Nucl Med. 2003;30:354-361.
29. Thames HD, Ang KK, Stewart FA, van Der Schuren E. Does incomplete repair explain the apparent failure of the basic LQ model to predict spinal cord and kidney responses to low doses per fraction? Int J Radiat Biol. 1988;54:13-19.
30. 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med. 2003;30:207-216.
31. 111In-DTPA] octreotide. J Nucl Med. 2004;45:1168-1171.
32. Dale R. Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy. Cancer Biother Radiopharm. 2004;19:363-369.
33. Thames HD, Bentzen SM, Turesson I, Overgaard M, Van den Bogaert W. Time-dose factors in radiotherapy: a review of human data. Radiother Oncol. 1990;19:219-235.
34. Joiner MC, van der Kogel AJ. The linear-quadratic approach to fractionation and calculation of isoeffect relationships. In: Steel GG, ed. Basic Clinical Radiobiology. London, UK: Arnold; 1997:106-122.